



RMB'000 *RMB'000*
(U a d ed) *(U a d ed)*

Re e e	180,679	208,531
G f ⁽¹⁾	80,702	84,443
Ne ()/ f ⁽²⁾⁽⁴⁾	(566,992)	94,925
Ba c ()/ea g e ha e (RMB)	(3.874)	0.594

Ne :

- (1) The g f f he G f he Re g Pe d a ed RMB80.7 . Ad ed g f cac a ed a he g f f he Re g Pe d, e c d g he ac f he e e e f ha e-ba ed a a d a da a f de fabe a g be a e de fed ac .
- (2) The G ec ded a e f RMB567.0 d g he Re g Pe d. The ad ed e f (he ) cac a ed a he f f he Re g Pe d e c d g he ac f ce a e h ch a e c de ed a - ea g b he a age e , c d g () he e e a e e e f ha e-ba ed a a d f RMB0.4 a d he e-ffe ee be ef e e e f RMB2.0 ; () he ga he f e g e cha ge a d e e a fa a e cha ge f RMB5.7 a g f he c e f H g K g d a de a ed c e be b d ed b he C a RMB, a d f e g e cha ge ga f RMB11.2 a a g f ca h a d ca h e ae ; () a a f de fabe a g be a e de fed ac f RMB15.3 ; () f a ca e e e he f a ca ab a a ed c f RMB4.8 ; () a e e a g be a e f RMB668.2 , a d he e e a f defe ed c e a ab e ca ed b he a e c da ed a g be a e f RMB50.3 . F he ca c a f he Ad ed Ne P f , a ac f he ad ed e e e c de ed.
- (3) F he C e d g Pe d f P e Yea , he ad ed e f he C e d g Pe d f P e Yea d d a e c de a he effec f he f a ca c e he f a ca ab a a ed c f RMB1.0 he ad ed e f . If h a a e c de a , he ad ed e f a d he ad ed e f ag f he C e d g Pe d f P e Yea ha be a f , e ec f h ch he G d d a e a ad e he e e d f he da a d c ed he C e d g Pe d f P e Yea :



RMB'000 *RMB'000*
(U a d ed) *(U a d ed)*

Ad ed e f	56,474	51,767
Ad ed e f a g	31.3%	24.8%

The following table sets forth the historical changes in the carrying amount of the Group's available-for-sale financial assets, net of impairment losses, as of the end of the reporting period (in RMB million).

		RMB'000 (Unaudited)	RMB'000 (Unaudited)
Carrying amount at the beginning of the year	3	180,679 (99,977)	208,531 (124,088)
Additions		80,702 (29,507)	84,443 (33,722)
Net impairment losses		(3,754)	
Disposals	7	(668,219)	
Other changes	4	3,492 5,344	515 42,579
Carrying amount at the end of the year		(611,942) 21,122 (11,094)	93,815 25,246 (6,122)
Impairment losses recognized in the profit and loss account	5	(601,914) 34,922	112,939 (18,014)
Impairment losses reversed in the profit and loss account		(566,992)	94,925
Impairment losses recognized in other comprehensive income		(566,992)	94,925
Other comprehensive income transferred to the profit and loss account		(535,403) (31,589)	82,029 12,896
Other comprehensive income transferred to equity		(566,992)	94,925
Balance at the end of the year (RMB million)	6	(3,874)	0.594
Balance at the beginning of the year (RMB million)	6	(3,874)	0.005

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.

| | | RMB'000
(U a d ed) | RMB'000
(A d ed) |
|-----------------------------------|---|-----------------------|---------------------|
| P e , a a d e e | | 143,168 | 146,176 |
| R g h - f - e a e | | 40,328 | 42,011 |
| I a g b e a e | 7 | 2,222,222 | 2,905,829 |
| D e f e d c e a a e | | 2,054 | 1,413 |
| O h e e c e a b e , d e a d e a e | | 2,901 | 2,012 |
| A d e f a e a e d a | | 80,000 | 80,000 |
| | | <hr/> | <hr/> |

| | | 2019
RMB'000
(Unaudited) | 2018
RMB'000
(Audited) |
|-------------------|----|--------------------------------|------------------------------|
| Beginning | | 69,462 | 99,658 |
| Change | 10 | 1,284,486 | 1,693,430 |
| Lease | | 316 | 650 |
| Deferred lease | | 300,153 | 350,087 |
| Accumulated lease | | 175 | 362 |

He C a a f Ch a L ed (he C a) a c a ed he Ca a I a d Feb a 21, 2014 a a e e ed c a h ed ab de he C a e La (Ca .22, La 3 f 1961 a c da ed a d e ed) f he Ca a I a d . The add e f he C a ' eg e ed ff ce PO B 309, Uga d H e, Ga d Ca a , KY1-1104, Ca a I a d .


The C a , ge he h b d a e (c ec e efe ed a he G), a e c a e gaged () e a a d a age e f ae ed h a ; () f a age e a d c a e ce hee -f - f h a a d () h e a e f ha ace ca d c he Pe e' Re b c f Ch a (he PRC_).

The C a c ed b Va g a d G L ed (Va g a d G), a b d a f H Ca a F d V, L.P., h ch c de ed a he a e h d g c a f he C a .

The d a ha e f he C a e e ed he Ma B a d f The S c E cha ge f H g K g L ed Ma ch 16, 2017.

The e c de ed c da ed f a c a f a e e ed Re b (RMB_) a d ded eae h a d a , e he e a ed.

Th e c de ed c da ed f a c a f a f he h e ded J e 30, 2020 ha bee e a ed acc da ce h I e a a Acc g S a da d (IAS_) 34,



O e a g e g e a e e ed a a e c e h he e a e g ded he ch ef
e a g dec - a e (CODM). The CODM, h e b e f a ca g e ce a d a e g

| | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
|----------------------------|----------------|------------------|----------------|------------|------------------|------------------|
| Segment operating income | 98,301 | 108,181 | 2,948 | (899) | | 208,531 |
| Interest expense | | | (899) | 899 | | |
| Reconciliation | <u>98,301</u> | <u>108,181</u> | <u>2,049</u> | | | <u>208,531</u> |
| Transaction fee | | | | | | |
| Administrative | 46,419 | | 2,049 | | | 48,468 |
| Other | 51,882 | 108,181 | | | | 160,063 |
| | <u>98,301</u> | <u>108,181</u> | <u>2,049</u> | | | <u>208,531</u> |
| EBITDA | 1,079 | 90,213 | (578) | 479 | | 91,193 |
| Depreciation | (3,673) | (1,016) | (285) | | (542) | (5,516) |
| Amortization | (3,787) | (11,858) | (191) | | (46) | (15,882) |
| Finance (income) / expense | (851) | 124 | 4 | | (2,126) | (2,849) |
| Unaudited change | | | | | 45,993 | 45,993 |
| (Loss) / Profit before tax | <u>(7,232)</u> | <u>77,463</u> | <u>(1,050)</u> | <u>479</u> | <u>43,279</u> | <u>112,939</u> |
| Segment assets | 414,247 | 1,588,475 | 3,557 | | 851,665 | 2,857,944 |
| Goodwill | 301,995 | 1,306,506 | 9,266 | | | 1,617,767 |
| Total assets | <u>716,242</u> | <u>2,894,981</u> | <u>12,823</u> | | <u>851,665</u> | <u>4,475,711</u> |
| Total liabilities | <u>143,038</u> | <u>358,906</u> | <u>2,148</u> | | <u>2,202,078</u> | <u>2,706,170</u> |

See Note 12 to the consolidated financial statements for further details.

| | RMB'000
(Unaudited) | RMB'000
(Unaudited) |
|---------------------------|------------------------|------------------------|
| Non-financial assets | 5,687 | 41,031 |
| Non-financial liabilities | 781 | 3,196 |
| Other | (1,124) | (1,648) |
| | <u>5,344</u> | <u>42,579</u> |

Subsidiaries accounted for 25% (15%) of the PRC consolidated revenue for the year ended June 30, 2019; 25% (15%) of the PRC consolidated revenue for the year ended June 30, 2020.

RMB'000
(Unaudited) RMB'000
(Unaudited)

Consolidated:

| | | |
|--------------------------|----------|--------|
| PRC consolidated revenue | 15,653 | 18,265 |
| Deferred revenue | (50,575) | (251) |
| | (34,922) | 18,014 |
| | (34,922) | 18,014 |

The consolidated financial statements of the Company are prepared in accordance with the accounting principles generally accepted in the United States of America.

Hong Kong accounted for 16.5% (16.5%) of the year ended June 30, 2019; 16.5% of the year ended June 30, 2020. Non-Hong Kong accounted for 83.5% (83.5%) of the year ended June 30, 2019; 83.5% of the year ended June 30, 2020.

The consolidated financial statements of the Company are prepared in accordance with the accounting principles generally accepted in the United States of America. The consolidated financial statements of the Company are prepared in accordance with the accounting principles generally accepted in the United States of America.

The holding company of the Special Limited Liability Company is 10% (10%) of the PRC E-commerce Inc. The holding company of the PRC e-commerce Inc. is 10% of the PRC e-commerce Inc.

Non-Performing Limited (Non-Performing) has been reclassified as Non-Performing Limited (Non-Performing) since the reclassification of the Non-Performing Limited (Non-Performing) from 2017 to 2019. After the reclassification, Non-Performing Limited (Non-Performing) has been reclassified as Non-Performing Limited (Non-Performing) since the reclassification of the Non-Performing Limited (Non-Performing) from 2017 to 2019. After the reclassification, Non-Performing Limited (Non-Performing) has been reclassified as Non-Performing Limited (Non-Performing) since the reclassification of the Non-Performing Limited (Non-Performing) from 2017 to 2019.

The holding company of the Non-Performing Limited (Non-Performing) has been 10%.

Balance/equity changes attributable to the Company before deduction of taxes paid on dividends, 2020 and 2019.

| | 2020 | 2019 |
|---|----------------|----------------|
| | (U.S. dollars) | (U.S. dollars) |
| Balance/equity changes attributable to the Company before deduction of taxes paid on dividends (in thousands) | (535,403) | 82,029 |
| Weighted average basic shares outstanding (in thousands) | 138,194 | 138,121 |
| Balance/equity changes (in RMB) | <u>(3.874)</u> | <u>0.594</u> |

The Company had the following equity changes during the period ended June 30, 2020 and the corresponding period ended June 30, 2019, respectively. The Company's equity changes are as follows:

| | 2020 | 2019 |
|---|----------------|----------------|
| | (U.S. dollars) | (U.S. dollars) |
| Balance/equity changes attributable to the Company before deduction of taxes paid on dividends (in thousands) | (535,403) | 82,029 |
| Change in fair value of equity securities (in thousands) | - | (80,994) |
| Balance/equity changes attributable to the Company before deduction of taxes paid on dividends (in RMB) | (535,403) | 1,035 |
| Weighted average basic shares outstanding (in thousands) | 138,194 | 138,121 |
| Additional shares issued (in thousands) | - | 64,694 |
| Weighted average basic shares outstanding (in thousands) | 138,194 | 202,815 |
| Change in equity (in RMB) | <u>(3.874)</u> | <u>0.005</u> |

| Ne b a e | | | | | |
|---------------------------|------------------|------------------|----------------|--------------|------------------|
| O e g a a a J a a 1, 2020 | 1,617,767 | 1,113,506 | 173,194 | 1,362 | 2,905,829 |
| A a | | (11,821) | (3,427) | (140) | (15,388) |
| I a e c h a g e | <u>(467,083)</u> | <u>(201,136)</u> | | | <u>(668,219)</u> |
| C g a a a J e 30, 2020 | <u>1,150,684</u> | <u>900,549</u> | <u>169,767</u> | <u>1,222</u> | <u>2,222,222</u> |

| Ne b a e | | | | | |
|---------------------------|------------------|------------------|----------------|--------------|------------------|
| O e g a a a J a a 1, 2019 | 1,617,767 | 1,137,153 | 180,047 | 1,572 | 2,936,539 |
| Add | | | | 178 | 178 |
| A a | | (11,823) | (3,427) | (160) | (15,410) |
| C g a a a J e 30, 2019 | <u>1,617,767</u> | <u>1,125,330</u> | <u>176,620</u> | <u>1,590</u> | <u>2,921,307</u> |

| | RMB'000
(U a d ed) | RMB'000
(A d ed) |
|---------------------------------|-----------------------|---------------------|
| T a d e e c e a b e | 35,106 | 31,332 |
| L e : f a e f a d e e c e a b e | <u>(4,754)</u> | <u>(1,000)</u> |
| T a d e e c e a b e e | <u>30,352</u> | <u>30,332</u> |

The carrying amount of the Group's trade receivables as at the end of the reporting period is RMB 35,106 thousand as at the end of the reporting period.

As at June 30, 2020 and December 31, 2019, the ageing analysis of trade receivables is as follows:

| | 2020
RMB'000
(Unaudited) | 2019
RMB'000
(Audited) |
|-------------------|--------------------------------|------------------------------|
| 1 - 90 days | 24,563 | 25,428 |
| 91 - 180 days | 1,153 | 1,658 |
| 181 days - 1 year | 5,234 | 2,947 |
| Over 1 year | 4,156 | 1,299 |
| | <u>35,106</u> | <u>31,332</u> |

The ageing analysis of trade receivables as at the end of the reporting period is as follows:

| | 2020
RMB'000
(Unaudited) | 2019
RMB'000
(Audited) |
|-------------------|--------------------------------|------------------------------|
| Within 90 days | 13,480 | 11,458 |
| 91 - 180 days | 2,464 | 971 |
| 181 days - 1 year | 301 | 372 |
| Over 1 year | 733 | 524 |
| | <u>16,978</u> | <u>13,325</u> |

The carrying amount of trade receivables as at the end of the reporting period is RMB 16,978 thousand as at the end of the reporting period.

The effect of the above items is as follows:

| | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
|--|----------------|----------------|----------------|------------------|
| At the beginning of the year | 392,174 | 577,039 | 724,217 | 1,693,430 |
| Decrease in fair value of financial assets | 2,318 | (7,633) | 120 | (5,195) |
| Change in fair value of financial assets | 10,696 | (6,141) | (9,878) | (5,323) |
| Aggregated financial assets (net)/gains (net) | (1,416) | 2,163 | (22) | 725 |
| Aggregated financial assets (net)/gains (net) as at Dec 31, 2020 | (515) | 4,707 | (86) | 4,106 |
| | <u>403,257</u> | <u>570,135</u> | <u>714,351</u> | <u>1,687,743</u> |
| At the beginning of the year | 430,241 | 643,615 | - | 1,073,856 |
| Increase in fair value of financial assets | - | - | 682,160 | 682,160 |
| Decrease in fair value of financial assets | 2,318 | (7,633) | 120 | (5,195) |
| Change in fair value of financial assets | (35,931) | (44,686) | 39,953 | (40,664) |
| Aggregated financial assets (net)/gains (net) | (642) | 636 | - | (6) |
| Aggregated financial assets (net)/gains (net) as at Dec 31, 2019 | (1,290) | 6,234 | (110) | 4,800,140 |

| | \ / / | Dece be 31,
2019 |
|-------------------|-------|---------------------|
| V a | / | 30% |
| T e e a (ea) | / , | 1.18 |
| R f e e a e f e e | / , , | 1.87% |
| D d e d e d | / / / | 0.00% |

A a J e 30, 2020, h e f a a e f h e c e b e b d a a a e HKD619,010,000, e a e a a e RMB565,428,000, h c h a d e e e d b a d e e d e a f e d a e .

The g f c a h e a a d e e a e d c e b e b d e d A g 7, 2018 e e e d a b e :

| | \ / / | Dece be 31,
2019 |
|-------------------|-------|---------------------|
| V a | / | 30% |
| T e e a (ea) | - / | 3.60 |
| R f e e a e f e e | / , , | 1.58% |
| D d e d e d | / / / | 0.00% |

A a J e 30, 2020, h e f a a e f h e c e b e b d a a a e HKD782,138,000, e a e a a e RMB714,437,000, h c h a d e e e d b a d e e d e a f e d a e .

The g f c a h e a a d e e a e d c e b e b d e d F e b a 27, 2019 e e e d a b e :

| | \ / / | Dece be 31,
2019 |
|-------------------|-------|---------------------|
| V a | / | 30% |
| T e e a (ea) | / , , | 4.16 |
| R f e e a e f e e | / , | 1.53% |
| D d e d e d | / / / | 0.00% |

P a a e f h e h a e h d e ' e e g f C H g h e F e b a 18, 2020, h e d d e d, c d g h h d g a , a g RMB5,355,000 a h a e h d e a d RMB2,295,000 h a e h d e a d e c a e d. The d d e d a h a e h d e a d h a e h d e h a d b e e e d F e b a 21, 2020.




In the first half of the year, according to the requirements of the National Health Commission's 2020 Work Key Points, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).

(1) In the first half of the year, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).

(2) In the first half of the year, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).

(3) In the first half of the year, the National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).


The National Health Commission has worked closely with the National Health Commission to carry out the work of the National Health Commission. In February, the Office of the Director General of the National Health Commission issued the Opinions on Deepening the Reform of the Medical Security System (《關於深化醫療保障制度改革的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》) and the CPC Central Committee issued the Opinions on the Key Work Departments of the Government Work Report (《國務院關於落實《政府工作報告》重點工作部門分工的意見》).



I he f ha f f he ea , de he g da ce f e a a eg , he G f b ed
 he c ehe e e gh f e e ea a d ea ea h ca ea e
 a de a e e a ec acc da ce h he e ab hed e ec c e a f e e
 ec , c d g c d c g e c a d -de h a a f a e a ac
 a ge e de fed aga e f he ae e a g c d , c ca g
 h a d de a d g f a e h a he e d c be f c ed b he G ,
 c d c g e e f ch h a , e cha ge a d d c ab fea be
 f ce a ec h a ed be a aged b he G h ch he G d
 de c g e ce , a a g f c he I e e hea hca e d , e g he
 e e a f I e e dag a d ea e de , a d c ba g ec ha c b e
 e a d ff e hea hca e e ce .

The G c d ced e e e ga e a ec e a ea ch a Ta ,
 J a g , A h , Zhe a g , Y a , G a gd ga d Ch g g . Ba ed he de c de a
 f e e c e a a d a fe e ea ed c ca h he he a e a d a a f
 he he he ec e e e a aged a d had g h e a , f he e ga ce a
 ec ha bee aba d ed he ea e e a ec ha e bee e ec ed . I he ec d
 ha f f he ea , he G ac e f he e ec , c e c d a e
 a a e ' e ce de f e e a ec , e he de e e f e e g g
 b e e ch a ha ac a e ' e e e (自費藥房) , ed ca g (醫生集團) a d
 I e e h a (互聯網醫院) , e ac e h a ed ca g h g eg a
 f e ce e d c e a d g ea de e e e a c e a e h he a
 a c da e a de a d he G ' e ce- ha g h a e . Mea h e , he
 G e ha ce eg be ee ad a a d I e e hea hca e a d g ad a ea e he
 G ' d e fed e e e de de a a d f da f a che g a eg c g a
 f cce f ac , e a age e , ca e e a (收到、管好、上量) .

A e e , he be f bed he h a ed , a aged f ded b he G ()
 e a he a ea ha a a he e d f 2019 .



The G ad ed c ehe e ea e f he G H a ch a ea g a eg c
 g , e f c g c a de e e , d g a age e , g cad e ,
 g e e , a g a ac g d- h gh- e d a e , h ch fac a ed he
 c ed a d a d hea h de e e f each G H a .

I he f haf f he ea , fac g he e e e c c a ce a d he C a D ea e 2019
 () a de c, he G ed a - e e c d a ed de e e de f
 e f a d he G H a , ded a d a e-added e ce G H a
 a e a ec a d c ed he ea a d c f he G a d
 he G H a e g he he c e a e e f G H a d g afe,
 c e e a d d g f ed ed ca e ce he e e_ I a c a , c de : (1) c g
 e he ga a , c e a d e c c f he head a e f he G
 e g he c ; (2) c g he e c a d a ce e f each fe a e
 f he G e g he e ec ; (3) c g e g e e a d e ge
 a d ac ec a d ec e e a e f ce he a eg f ca e e a
 (上量); (4) c g e ce ha g be ee he G a d G H a
 e ha ce e g ; (5) c g he f a a c c f he G a d
 G H a e g he he da a f da ; (6) c g he ad e a d
 c c f he ea ea f G H a e g he eade h ; (7) c g
 c a e e f he ea f G H a e g he he effec f
 e ha ce e ; (8) c g he eg a f ed ca a d hea hca e b g da a, AI,
 f a ce a d a ce d e f a ; a d (9) c g he a da d a
 a d a age e f he ed c a e g he c ec h ha eh de a d e ce
 he ca a a e . The ea ea g effc e c a d e f a ce f G H a dec ed
 he f haf f he ea d e he COVID-19 a de c, h ch a e e ec ed e he
 ec d ha f f 2020.

I he f haf f he ea , gh f he e a d a COVID-19 a de c ha ca ed
 d ce a b e a d h ge e a g e e h a , he G a d he G
 H a ed ge he a d ad ed a ea e ce a e he be f - a e ,
 - a e a d g ca ea . A affec ed b e e a bec e fac , a b e
 d ca f G H a dec ed gh he c a ed h he C e d g Pe d
 f Pe Yea . D g he Re g Pe d, he G H a ec ded a ae
 1,048,985 - a e , e e e g a 20% dec ea e he c a ed h 1,311,487
 - a e f he C e d g Pe d f Pe Yea ; a ae 37,622 - a e
 , e e e g a dec ea e f 17% he c a ed h 45,499 - a e f he
 C e d g Pe d f Pe Yea ; a ae 7,681 g ca ea , e e e g
 a dec ea e f 11% he c a ed h 8,641 g ca ea f he C e d g Pe d
 f Pe Yea . The G ha ach e ed e a abe e c a g he
 eg a ed ea a d a age e f he G H a , h ch ha a da d f da
 f he c g a d a d hea h g h f each G H a he f e . A he c e
 COVID-19 a de c a he PRC c e b bec g abe e, he ea g
 b e e f a ce f he G H a g ad a ec e g . I e ec ed ha he
 b e (c d g he e f - a e , - a e a d g ca ea f
 G H a) f he G 2020 be affec ed b COVID-19, b he ac ea
 c abe e.

(6) C a he e g f e ce a g G H a a d
g eade h a d e ce ha g f eg a ed ca ce e , a d ac e
ceed g h he c e ce e f de a ec d g he e acade c
bec fe ; a d

(7) Reg a g he a age e f he C a a d e g he g a age e ,
e ha c g effec e c ec h he ca a a e a d cea g he b a d f e ce
f he G he ca a a e , de a a g d f da f he f a c g
de e e f he G .

→

↑ ↓ ↖ ↗

D g he Re g Pe d, e e e a RMB180.7 , e e e g a dec ea e f
a ae 13.4% he c a ed h RMB208.5 f he C e d g Pe d f
Pe Yea , h ch a a a b abe a dec ea e a age e e ce fee de ed
f Sha gha Ya g H a * (上海楊思醫院) () a d Zhe a g J h a
G a gf Oc g ca H a * (浙江金華廣福腫瘤醫院) () a d a dec ea e
he a f e e e f he f ge e a h a e ce b Ja de H a f
T ad a Ch e e Med c e C ., L d.* (建德中醫院有限公司) () d d a
a e .

O e e e f he h a a age e e ce eg e c ded e e e f he
f h a a age e e ce Ya g H a , C U H a * (慈溪協和
醫院) () a d J h a H a . D g he Re g Pe d, he e e e f h
eg e a RMB101.0 , e e e g a dec ea e f 6.6% he c a ed h RMB108.2
f he C e d g Pe d f Pe Yea . The dec ea e e e e a a
a b abe he ac f COVID-19 a de c, h ch ca ed a dec ea e he a age e
e ce fee ec g ed f d g e ce Ya g H a a d J h a H a .

D g he Re g Pe d, e e e f he ge e a h a e ce eg e dec ea ed
b a ae 19.1% RMB79.6 f RMB98.3 he C e d g Pe d
f Pe Yea . Re e e f h eg e f he Re g Pe d dec ea ed a d e
a dec ea e he a f e e e f he f ge e a h a e ce b Ja de
H a d d a a e , h ch a he e f he dec ea e he be f - a e
a d - a e f Ja de H a f he Re g Pe d a affec ed b he COVID-19
a de c.

O ad ed g f a RMB96.4 f he Re g Pe d, e c d g he ac
f e e e f ha e-ba ed a a d a da a f de f abe a g be a e de fed
ac , e e e g a dec ea e f a ae 6.1% he c a ed h RMB102.6
f he C e d g Pe d f Pe Yea . Th a a a b abe he ac
f COVID-19 a de c, h ch ca ed a dec ea e he a age e e ce fee ec g ed f
d g e ce Ya g H a a d J h a H a .

We ec ded ad ed ad a e e e e f RMB27.5 f he Re g Pe d,
e c d g he ac f he e-ffe ee be ef e e e , e e e g a dec ea e f
14.1% he c a ed h RMB32.0 f he C e d g Pe d f Pe Yea ,
h ch a a d e a dec ea e fe a e ce fee f he Re g Pe d he
c a ed h he C e d g Pe d f Pe Yea .

We ec ded ad ed e a g f f RMB68.3 f he Re g Pe d, a dec ea e f
a a e RMB4.4 f RMB72.7 f he C e d g Pe d f P e
Yea . Th a d e he ac f COVID-19 a de c, h ch ca ed a dec ea e he
a age e e ce fee ec g ed f d g e ce Ya g H a a d J h a H a .

We ec ded ad ed f a ce c e (e) f RMB3.6 f he Re g Pe d, e c d g
he ac f f e g e cha ge ga a e a g ca h a d ca h e a e , a d f a c a
e e e he f a c a ab a a ed c , e e e ga cea e f RMB6.5
he c a ed h he f a ce e e e (e) (e c d g he effec f f e g e cha ge ga
a e a g ca h a d ca h e a e , a d he f a c a c e he f a c a ab
a a ed c f RMB1.0) f RMB2.9 f he C e d g Pe d f P e
Yea . The cea e f a ce c e (e) a a d e a cea e f RMB6.7
e e c e f a a e a ed a , de a d de , e de a d de he d a ca
he c a ed h he C e d g Pe d f P e Yea .

F he Re g Pe d, e ha e ec ded a Ad ed Ne P f f RMB56.5 ,
e e e ga cea e f a a e 9.1% he c a ed he ad ed e f f
RMB51.8 f he C e d g Pe d f P e Yea (e c d g he effec f f a c a
c e he f a c a ab a a ed c f RMB1.0 f he C e d g
Pe d f P e Yea). W h a g acc he ac f he ad ed e , ch
cea e a a d e he dec ea e c e a e e e f RMB2.7 he
c a ed h he C e d g Pe d f P e Yea (h ch a d e he dec ea e
he e a g f f he G), a d he f a ce c e (e) f he Re g Pe d ha
cea ed b RMB6.5 a c a ed he f a ce e e e (e) f he C e d g
Pe d f P e Yea .



A a J e 30, 2020, a e a RMB1,249.4 (a a Dece be 31, 2019:
RMB1,817.8). A a J e 30, 2020, e had c e a e f RMB1,339.1 (a
a Dece be 31, 2019: RMB1,277.5) a d c e ab e f RMB925.9 (a
a Dece be 31, 2019: RMB492.9). A a J e 30, 2020, c e a a 1.45, a
c a ed h 2.59 a a Dece be 31, 2019.

O c e a e cea ed b a a e RMB61.6 f a a e RMB1,277.5
a a Dece be 31, 2019 RMB1,339.1 a a J e 30, 2020, a d e a
c ea e e ce ab e f e a ed a e a d f a c a a e a fa a e h gh f
acc g. O c e ab e cea ed b RMB433.0 f RMB492.9 a
a Dece be 31, 2019 RMB925.9 a a J e 30, 2020, a d e he f
c e be b d ha a e h e ea .

O a e f ca h he Re g Pe d e e f g ca a , e de a d
a e f f a c a a e a fa a e h gh f acc g. We f a ced
d e e e a h ca h f ge e a ed f e a g ac e . A a J e
30, 2020, e had ba b g f RMB215.0 (a a Dece be 31, 2019: RMB214.4
) , a d e had ca h a d ca h e a e f RMB922.5 (a a Dece be 31, 2019:
RMB836.6). O D ec be e ed ha , a fe a g acc he f a c a e ce
a a ab e , h ch c de e a ge e a ed f d a d he e ceed f he L g, e
had ff ce g ca a ee eed . A a J e 30, 2020, he G d d ha e a
he a e a c ge ab e g a a ee .


N a e a b e e e e a d e a e b h e C a b h e G a f e J e 30, 2020
a d h e d a e f h a c e e .

The C a h a a d e d h e c d e a e h e C a e G e a c e C d e (h e
c a e d A e d 14 h e R e G e g h e L g f S e c e T h e
S c E c h a g e f H g K g L e d (). E c e f a d c e d b e , h e
B a d c d e h a , d g h e R e g P e d , h e C a h a c e d h h e a c a b e
c d e e h e C G C d e . T h e C a c e e e e a d e h a c e
c a e g e a c e a c c e e e c a c e h h e C G C d e .

P A.2.1 f h e C G C d e a e h a h e e f c h a a a d c h e f e e c e f f c e
h d b e e a a e a d h d b e e f e d b h e a e d d a . M . S H A N G h a
e g e d a h e c h e f e e c e f f c e f h e C a () a d M .
Z H A O J h H a h a e g e d a h e c h a a f h e B a d h e f f e c f J e 23, 2020 . O
h e a e d a e , M . C H E N S h a h a b e e a e d a h e c h a a f h e B a d
a d h e a c g C h e f E e c e O f f c e . M . C H E N e e a h e a c g C h e f E e c e
O f f c e h e B a d a a e C h e f E e c e O f f c e . T h e B a d h e c e f
M i n i s t e r o f t h e C e n t r a l F i n a n c e M i n i s t r y a n d 1120.11(N C h a f h d 67 T B 2 a B f a B a d e a 16, 72020.38), 2020



Th a ce e b hed he eb e f he H g K g E cha ge a d C ea g
 L ed (.h e e .h) a d he C a (.hcc hea hca e.c). The e e f
 he C a f he Re g Pe d be d a ched he ha eh de f he C a a d
 ade a a ab e f e g he ab e eb e d ec e.



B de f he B a d

Cha a

Be g, Ch a, A g 28, 2020

A a he da e f h a ce e , he D ec f he C a a e M . SU Zh a g a d M .
 LU We be g he e ec e D ec ; M . CHEN Sh a , M . SHI We g , M . LIU L a d
 M . WANG Na be g he -e ec e D ec ; a d M . DANG J e , M . SHI L e a d
 M . ZHOU X a g a g be g he de e de -e ec e D ec .

* F de fca e